Tetra Bio-Pharma Inc. today announced it is ready to resume its Phase 3 clinical program in advanced cancer pain patients with the objective to assess Health- Related Quality of Life (HrQoL).
Tetra Bio-Pharma Inc. today announced that the Company has renewed its CEO Guy Chamberland’s employment agreement.
Tetra Bio-Pharma Inc. today announced it is ready to submit its PPP001 cannabinoid-derived drug as a herbal medicinal product to the European Medicines Agency.
Tetra Bio-Pharma Inc. today announced the promotion of Aurelia De Pauw to Vice-President, Clinical Programs and Medical Affairs. In her new role Dr. De Pauw will be responsible for of all clinical operations and relations with the medical community, building Tetra Bio-Pharma’s clinical department and ensuring it continues to meet the highest standards of a pharmaceutical company.
Tetra Bio-Pharma Inc. is pleased to announce completion of the first double-blind, randomized and placebo-controlled Phase 2 clinical trial of cannabis oil capsules.
According to a recent Ipsos poll commissioned by Tetra Bio-Pharma, it seems that Canadians believe that Doctor Knows Best when it comes to recommending cannabis for a medical ailment, even though they are less convinced that they are well enough informed to treat them with it.
Tetra Natural Heath announces that Hemp Energy Drink cans are now available in 59 grocery stores and convenience stores in British Columbia, Alberta, and Saskatchewan.
Tetra Bio-Pharma Inc. today announced accelerated development of its second-generation drug inhalation program for fibromyalgia and uncontrolled pain over the last months.
Tetra Bio-Pharma Inc. announces today that it has granted, pursuant to the Company's stock option plan (the "Plan"), 375,000 options to officers of the Company. Each option entitles its holder to purchase one common share of the Company.
Tetra Bio-Pharma Inc. today announced a change in their Drug Development Plan (DDP) priorities. This will allow Tetra to rapidly leverage the PANAG pipeline and expertise and align its research programs on indications with unmet medical needs or a higher return on investment (ROI).